comparemela.com

Latest Breaking News On - Enanta pharmaceuticals stock down - Page 1 : comparemela.com

Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $27.00 Price Target at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $27.00 Price Target at HC Wainwright
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Enanta-pharmaceuticals
Analyst-recommendations-for-enanta-pharmaceuticals
Armistice-capital
Krensavage-asset-management
News-ratings-for-enanta-pharmaceuticals-daily
Enanta-pharmaceuticals-inc
Acadian-asset-management
Hermes-inc
Enanta-pharmaceuticals-stock-down
Jpmorgan-chase-co
Get-free-report

Virtus ETF Advisers LLC Sells 1,654 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Virtus ETF Advisers LLC lowered its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 11.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 12,784 shares of the biotechnology company’s stock after selling 1,654 shares during the period. Virtus ETF Advisers LLC’s holdings in Enanta Pharmaceuticals were worth $143,000 […]

Terry-vance
Quarter-for-enanta-pharmaceuticals
Clearstead-advisors
Nasdaq
Daymark-wealth-partners
News-ratings-for-enanta-pharmaceuticals-daily
Holdings-channel
Jump-financial
Enanta-pharmaceuticals-stock-down
Enanta-pharmaceuticals
Enanta-pharmaceuticals-inc
Securities-exchange-commission

Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to "Hold" at Jefferies Financial Group

Jefferies Financial Group cut shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a buy rating to a hold rating in a research note released on Tuesday, MarketBeat.com reports. They currently have $18.00 price target on the biotechnology company’s stock, down from their previous price target of $49.00. ENTA has been the topic of a […]

Texas
United-states
Canada
Enanta-pharmaceuticals
Enanta-pharmaceuticals-company-profile
Abbott-laboratories
Texas-permanent-school-fund-corp
Jump-financial
News-ratings-for-enanta-pharmaceuticals-daily
Enanta-pharmaceuticals-inc
Renaissance-technologies

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) in a research note published on Tuesday morning, Benzinga reports. They currently have a $48.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2024 earnings at ($2.61) EPS, Q3 2024 earnings at […]

Canada
Acadian-asset-management
Enanta-pharmaceuticals
Analyst-recommendations-for-enanta-pharmaceuticals
Jefferies-financial-group
News-ratings-for-enanta-pharmaceuticals-daily
Institutional-trading-of-enanta-pharmaceuticals
Abbott-laboratories
Enanta-pharmaceuticals-inc
Commonwealth-of-pennsylvania-public-school-empls-retrmt
Royal-bank

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective […]

Blackrock
Nova-scotia
Canada
Montreal
Quebec
Piper-sandler
Paulj-mellett
Enanta-pharmaceuticals
Nasdaq
Enanta-pharmaceuticals-inc
Metlife-investment-management
Jpmorgan-chase-co

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.